Sarcoma News and Research

RSS

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb Company, a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 3-7.

21 May 2011

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Eli Lilly and Company announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body.

20 May 2011

Reprogrammed herpes virus can improve early cancer diagnosis

Scientists have used a genetically re-engineered herpes virus that selectively hunts down and infects cancerous tumors and then delivers genetic material that prompts cancers to secrete a biomarker and reveal their presence.

12 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

Mary Ann Liebert publishes new journal on cancer care for adolescent and young adult patients

The field of adolescent and young adult oncology reflects the growing recognition that this group of patients and survivors are not just "old" pediatric patients or "young" adult patients.

9 May 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

ZIOPHARM Oncology, Inc, an oncology small molecule and synthetic biology drug development company, today reported its financial results for the three months ended March 31, 2011, and provided an update on the Company's activities in the first quarter.

5 May 2011

Centocor Ortho Biotech Products withdraws NDA for trabectedin for treatment of women with ROC

Centocor Ortho Biotech Products, L.P., today announced that it has voluntarily withdrawn the New Drug Application for trabectedin for the treatment of women with recurrent ovarian cancer. The withdrawal is based on the U.S. Food and Drug Administration's recommendation that an additional Phase 3 study be conducted to obtain approval.

30 Apr 2011

FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug designation for the treatment of patients with pancreatic cancer by the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA). CytRx holds the exclusive worldwide development and commercialization rights to INNO-206.

28 Apr 2011

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the publication of a case report in the peer-reviewed Journal of Clinical Oncology documenting the use of tamibarotene in the successful treatment of a patient with recurrent advanced-stage acute promyelocytic leukemia.

19 Apr 2011

NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the Phase 2 portion of the Small Business Innovation Research Grant from the National Cancer Institute under the agency's Streamlined Non-competing Award Procedures.

11 Apr 2011

Research on rare cancers

A cancer diagnosis can be a life-changing event. Many questions arise, with one of the first being, "Where should I be treated?" Patients diagnosed with rare cancers may have difficulty finding a physician knowledgeable in treating their type of cancer.

11 Apr 2011

Hartwell honors UCSD scientists with Individual Biomedical Research Award

Three scientists at the University of California, San Diego School of Medicine are among this year's 12 winners of Hartwell Individual Biomedical Research Awards, honoring researchers whose work advances children's health.

7 Apr 2011

Zebrafish research suggests new drug targets and markers to help treat melanoma

Thanks to the zebrafish, there is new hope for people with melanoma, an aggressive skin cancer that is responsible for approximately 8,700 deaths each year in the United States.

5 Apr 2011

AIDS people may face high risk of stomach and esophageal malignancies

Among people with AIDS, the risk of stomach and esophageal malignancies is higher than among the general population, according to study results presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

5 Apr 2011

Molecular pharmacologist receives AACR Award for cancer research

Susan Band Horwitz, Ph.D., will receive the Eighth Annual AACR Award for Lifetime Achievement in Cancer Research. Horwitz conducted pioneering research by discovering the mechanism of action of the chemotherapeutic drug paclitaxel, which prompted the development of this drug as an important therapy for many common solid tumors, including ovarian, breast, and lung carcinomas.

28 Mar 2011

FDA approves ipilimumab for metastatic melanoma treatment

The U.S. Food and Drug Administration announced today its approval of a new treatment for advanced melanoma, the deadliest and most difficult-to-treat form of skin cancer.

28 Mar 2011

CytRx commences INNO-206 Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial will include up to 24 patients with advanced solid tumors who have failed standard therapies.

17 Mar 2011

TESE offers fertility to male cancer survivors

An intricate procedure that finds and carefully removes individual sperm from testicular tissue has made fathers of men who were once considered sterile due to prior cancer treatment, say researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center who pioneered the technique.

16 Mar 2011

TESE surgical technique can help men with childhood cancer experience parenthood

A new study has shown that a surgical technique called microdissection testicular sperm extraction can effectively locate and extract viable sperm in more than one-third of adult male childhood cancer survivors who were previously considered sterile due to prior chemotherapy treatment.

15 Mar 2011

Survey: Most HIV-positive patients die of cancer

Most HIV-positive patients die of cancer. In the latest issue of Deutsches Ärzteblatt International, Manfred Hensel's research group presents epidemiological data.

9 Mar 2011